Medications
IBAT
Ileal Bile Acid Transporter Inhibitors
About this Treatment
IBAT inhibitors such as Maralixibat (aka Livmarli) and Odevixibat (aka Bylvay) disrupt the enterohepatic circulation and lead to fecal elimination of bile acids.
The term “enterohepatic circulation” denotes the movement of bile acid molecules from the liver to the small intestine and back to the liver.
To treat itch.
Your Experience
Matters
Date Last Updated:
10/12/2024
Community Experiences
Recorded: 14
Recorded: 14
Community
Experiences
PFIC patients & the community have
reported the following experiences:
Benefits
- Can result in complete disappearance of itch, specifically in BSEP deficiency (PFIC 2).
- Parents of FIC1 and MYO5B deficient children also reported important improvements in itch reduction.
- Parents reported important improvements in sleep quality and patient and family quality of life.
- Parents reported improved weight, growth, and development.
- Parents reported improved mental health due to better social life (playing with other children).
- Parents reported that it eliminated the need for other itch medications which had to be taken multiple times a day.
Burdens
- In some cases worsened liver labs.
- In some cases periods of diarrhea.
- Patients report high expense if not covered or provided on compassionate grounds (country specific).
- Access is country specific, applications for compassionate drug use can take considerable time and success is not guaranteed.
Impacted Areas
of Patient Life
Of the six main areas mainly affected by PFIC, patients & the community have identified the areas impacted by this medication.
Resources
If you’d like to learn more you can
do so by visiting our Resource page.
Feedback
Have any feedback regarding this Web App?
We’d love to hear from you!
Close
Medications
Ileal Bile Acid Transporter Inhibitors
Close
Contribute